window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : June 10, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

oncology

  • Clinical & Regulatory,Pharmaceuticals and therapeutics,Therapeutic Areas

    Talquetamab recommended by NICE for relapsed and refractory multiple myeloma

    The National Institute for Health and Care Excellence (NICE) has [...]

    May 5, 2026
  • Clinical & Regulatory,Pharmaceuticals and therapeutics,Therapeutic Areas

    FDA approves Kura and Kyowa Kirin’s ziftomenib for relapsed or refractory AML

    The US Food and Drug Administration (FDA) has approved KOMZIFTI [...]

    May 5, 2026
  • Clinical & Regulatory,Pharmaceuticals and therapeutics,Therapeutic Areas

    Otsuka submits EMA application for Inaqovi and venetoclax combination to treat acute myeloid leukaemia

    Otsuka Pharmaceutical Europe has submitted a marketing authorisation application (MAA) [...]

    May 5, 2026
  • Drug Discovery & Development,Genomics and sequencing

    SPT Labtech and Agilent launch automated target enrichment workflows for genomic sequencing

    SPT Labtech and Agilent Technologies have introduced automated target enrichment [...]

    May 5, 2026
  • Clinical & Regulatory,Therapeutic Areas

    MaaT Pharma’s Phase 2b Phoebus trial cleared to continue after positive safety review

    MaaT Pharma has reported a positive outcome from the second [...]

    May 5, 2026
  • Biotech & Pharma Business,Clinical & Regulatory,Pharmaceuticals and therapeutics,Therapeutic Areas

    Kairos Pharma to present Phase 2 prostate cancer data at ESMO 2025

    Kairos Pharma, Ltd. will present positive safety and early efficacy [...]

    May 5, 2026
  • Biotech & Pharma Business,Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Therapeutic Areas

    CytoAgents receives fourth NIH grant to advance research on cytokine release syndrome in CAR T-cell therapy

    CytoAgents, a clinical-stage biotechnology company developing an oral small-molecule immune [...]

    May 5, 2026
  • Biotech & Pharma Business,Drug Discovery & Development,Therapeutic Areas

    Myricx Bio appoints Boston-based Mohit Rawat as CEO and expands team in US and UK

    Myricx Bio has appointed Boston-based Mohit Rawat as chief executive [...]

    May 5, 2026
  • Clinical & Regulatory,Drug Discovery & Development,Therapeutic Areas

    UK approves cabozantinib Ipsen for previously treated advanced neuroendocrine tumours

    The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has [...]

    May 5, 2026
  • Advanced Therapies,Drug Discovery & Development,Pharmaceuticals and therapeutics

    N4 Pharma advances targeted RNA delivery with SRI collaboration

    N4 Pharma plc, the UK biotech developing its proprietary Nuvec® [...]

    May 5, 2026
Previous234Next

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Evogene reports Phase 1 results for microbiome therapy BMC128 with nivolumab
    Categories: Clinical & Regulatory, Pharmaceuticals and therapeutics, Therapeutic Areas
  • IMU Biosciences extends Series A to $53M to advance immune profiling platform
    Categories: Biotech & Pharma Business, Digital & Data
  • LotusDx opens Aberdeen R&D laboratory to advance at-home STI testing
    Categories: Biotech & Pharma Business, Medical devices
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top